Apimeds Pharmaceuticals US (APUS) Convertible Debt (2024 - 2025)
Apimeds Pharmaceuticals US's (APUS) quarterly Convertible Debt came in at $235439.0 in Q3 2025, little changed quarter-over-quarter from $235439.0 in Q2 2025.
Powered by 
Analysis
Apimeds Pharmaceuticals US (APUS) Convertible Debt (2024 - 2025) Analysis & Trends
Apimeds Pharmaceuticals US (APUS) has reported Convertible Debt for 2 consecutive years, with $235439.0 the latest figure, recorded in Q3 2025.
- For the quarter ending Q3 2025, Convertible Debt changed N/A year-over-year to $235439.0; the trailing twelve-month figure through Sep 2025 stood at $235439.0 (changed N/A YoY), and the FY2024 full-year result was $346844.0, changed N/A from the prior year.
- Convertible Debt steadied at $235439.0 in Q3 2025 per APUS's latest filing, from $235439.0 in the prior quarter.
- Across five years, Convertible Debt topped out at $346844.0 in Q4 2024 and bottomed at $235439.0 in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn |
| 10 | Apimeds Pharmaceuticals US | 3.79 Mn | 3.79 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2025 | 235,439.00 |
| Jun 30, 2025 | 235,439.00 |
| Dec 31, 2024 | 346,844.00 |